Sionna Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Sionna reported Q2 2026 net loss of $29.9M (vs. $18.1M YoY), with R&D expenses of $21.9M and G&A of $10.6M. Two key clinical milestones remain on track: PreciSION CF Phase 2a trial of SION-719 (add-on to standard of care for CF, enrollment completed April 2026) and Phase 1 dual combination trial of SION-451 with SION-2222 and SION-109 in healthy volunteers—both targeting topline data summer 2026. Cash position of $268.3M as of June 30, 2026 is expected to fund operations into 2028.
Why this rating
Routine quarterly disclosure. Loss acceleration (65% YoY) and cash burn modest relative to $342M market cap and 2-year runway. No deal, no milestone hit, no restatement; data pending.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.